{"doi":"10.1002/cam4.5011","title":"Vaccines against <scp>SARS‐CoV</scp>‐2 are safe to administer in patients with antibodies to pegaspargase","abstract":"OBJECTIVE: Allergic reactions to pegaspargase during ALL therapy are typically due to antibodies against polyethylene glycol (PEG), which is also used as a stabilizing agent in mRNA-based SARS-CoV-2 vaccines. To evaluate the safety of these vaccines in patients with anti-pegaspargase antibodies. METHODS: We retrospectively reviewed the records of patients treated for ALL who had received SARS-CoV-2 vaccinations. All patients had antibodies against pegaspargase assayed during ALL therapy prospectively and in response to clinical allergies. Symptoms of intolerance to vaccination were gathered retrospectively from chart abstraction. RESULTS: SARS-CoV-2 vaccination was well tolerated in all 78 patients with prior exposure to pegaspargase as part of their leukemia therapy. No reactions were observed in the 54 patients without a history of anti-pegaspargase antibodies or in 19 patients with antibodies who received mRNA vaccination. 1 patient who received the polysorbate containing Janssen vaccine experienced mild symptoms after vaccination not meeting the criteria of clinical allergy which spontaneously resolved within 25 minutes. CONCLUSION: SARS-CoV-2 vaccination is safe in this population.","journal":"Cancer Medicine","year":2022,"id":309855,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9489,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":423505,"name":"Hana Hakim","orcid":"0000-0001-7146-5452","position":1,"is_corresponding":false},{"id":423504,"name":"Diego R. Hijano","orcid":"0000-0002-2903-666X","position":2,"is_corresponding":false},{"id":785688,"name":"Ted Morton","orcid":"0009-0008-3590-2086","position":3,"is_corresponding":false},{"id":785687,"name":"Shane J. Cross","orcid":"0000-0001-7287-6851","position":4,"is_corresponding":false},{"id":285762,"name":"Hiroto Inaba","orcid":"0000-0003-0605-7342","position":5,"is_corresponding":false},{"id":285763,"name":"Sima Jeha","orcid":"0000-0003-2835-5869","position":6,"is_corresponding":false},{"id":254773,"name":"Ching‐Hon Pui","orcid":"0000-0003-0303-5658","position":7,"is_corresponding":false},{"id":254764,"name":"Seth E. Karol","orcid":"0000-0001-8113-8180","position":8,"is_corresponding":false},{"id":451829,"name":"Hope D. Swanson","orcid":"0009-0000-2490-9655","position":0,"is_corresponding":true}],"reference_count":16,"raw_metadata":null,"created_at":"2026-07-19T00:33:15.860993Z","pmid":"35837830","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}